Literature DB >> 7982642

Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis.

D Moradpour1, J Altorfer, R Flury, P Greminger, C Meyenberger, R Jost, M Schmid.   

Abstract

We describe a 33-yr-old pregnant woman in whom a primary biliary cirrhosis-like syndrome developed after 2 wk of chlorpromazine therapy. The clinical course was characterized by severe jaundice lasting 22 mo, intense pruritus, fever, steatorrhea, high alkaline phosphatase levels and hypercholesterolemia. Jaundice resolved with initiation of ursodeoxycholic acid therapy, but subclinical cholestasis and low-level inflammatory activity persisted and ultimately evolved into biliary cirrhosis. The pathological substrate of this severe and prolonged cholestatic reaction was found to be the vanishing bile duct syndrome with a marked transient pseudoxanthomatosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982642     DOI: 10.1002/hep.1840200610

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Erythromycin-induced primary biliary cirrhosis.

Authors:  D A Lazarczyk; M C Duffy
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 2.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 3.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Authors:  Kyunghee Yang; Kathleen Köck; Alexander Sedykh; Alexander Tropsha; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2013-05-07       Impact factor: 3.534

4.  Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.

Authors:  Rajan Kochar; Moises I Nevah; Frank J Lukens; Michael B Fallon; Victor I Machicao
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

5.  The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity.

Authors:  Wenqing Mu; Guang Xu; Ziying Wei; Zhilei Wang; Qin Qin; Li Lin; Lutong Ren; Tingting Liu; Zhie Fang; Yan Yang; Jing Zhao; Junnan Wang; Xiaoyan Zhan; Xiaohe Xiao; Zhaofang Bai
Journal:  Cell Death Discov       Date:  2022-07-09

Review 6.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

7.  Drug associated vanishing bile duct syndrome combined with hemophagocytic lymphohistiocytosis.

Authors:  Hui Li; Xin Li; Xiao-Xing Liao; Hong Zhan; Yan Xiong; Chun-Lin Hu; Hong-Yan Wei; Xiao-Li Jing
Journal:  World J Gastrointest Endosc       Date:  2012-08-16

Review 8.  Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.

Authors:  Jason C White; Stephanie Appleman
Journal:  Pediatrics       Date:  2014-09-22       Impact factor: 7.124

9.  Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.

Authors:  Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins
Journal:  Am J Gastroenterol       Date:  2015-09-08       Impact factor: 10.864

10.  Long-Term Outcomes After Drug-Induced Liver Injury.

Authors:  Paul H Hayashi; Einar S Bjornsson
Journal:  Curr Hepatol Rep       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.